Elderly patients who undergo cataract surgery will now have the option of receiving a single injection of Dexycu immediately following surgery.
Dexycu was approved by the Food and Drug Administration as a treatment for inflammation associated with cataract surgery.
Currently, post-operative treatment consists of burdensome self-administration of medicated eyedrops multiple times a day over several weeks. The new, single-injection of Dexycu would eliminate that protocol. The drug was found to be effective in reducing inflammation and proved to be as safe as a placebo.
Both physicians and patients will appreciate the convenience and physicians will not have to worry about noncompliance and dosing errors for their patients, which is extremely common with the eyedrop protocol.